Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
|Articles|November 18, 2021
Daily Medication Pearl: Aducanumab-avwa (Aduhelm) for Alzheimer Disease
Author(s)Saro Arakelians, PharmD
Aducanumab-avwa is a human, immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta.
Advertisement
Medication Pearl of the Day: Aducanumab-avwa (Aduhelm)
Indication: Aducanumab-avwa is an amyloid beta-directed antibody indicated for the treatment of Alzheimer disease.
Insight:
- Dosing: The recommended maintenance dosage is 10 mg/kg administered as an intravenous infusion over approximately 1 hour every 4 weeks.
- Dosage form: 170 mg/1.7 mL (100 mg/mL) solution in a single-dose vial and 300 mg/3 mL (100 mg/mL) solution in a single-dose vial.
- Adverse events (AEs): Most common AEs (at least 10% and higher incidence compared to placebo): ARIA-Edema, headache, ARIA-H microhemorrhage, ARIA-H superficial siderosis, and fall.
- Mechanism of action: Aducanumab-avwa is a human, immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta.
- Manufacturer: Biogen
Sources:
Advertisement
Related to this article
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Novo's topline phase 3 data show 12.4% weight loss with CagriSema 1.0 mg/1.0 mg in type 2 diabetes and 21.0% in adults with overweight or obesity.
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Ramantamig's 93.6% ORR and Outpatient CRS Control
2
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
3
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
4
Influenza Vaccines Continue to Reduce Severe Disease and Death Across High-Risk Groups, Evidence Review Finds
5